조직 진단 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Tissue Diagnostics Market Growth & Trends:

The global tissue diagnostics market size is expected to reach USD 14.03 billion by 2030, registering a CAGR of 8.41% from 2025 to 2030, according to a new report by Grand View Research, Inc. Accelerating demand for automated tissue diagnostic systems due to a lack of skilled pathologists has driven the tissue diagnostics industry. The advent of advanced imaging techniques, such as autofluorescence, that minimize the need for invasive diagnostics further supplements the market growth.

The use of digital slides has significantly increased in recent years, owing to its associated benefits including flexible magnification and remote access to slides. The growing emphasis on precision medicine is supported by several organizations & companies in the U.S., which is expected to contribute to the market growth. Additionally, companies are supporting the development of precision medicine with novel oncology solutions. For instance, in May 2020, QIAGEN launched new oncology solutions, such as the QCI Interpret One software solution for genomic profiling of tumors. The advancements in imaging techniques are expected to positively influence market growth.

In addition, one of the emerging trends in the tissue diagnostics industry is the integration of digital pathology and artificial intelligence (AI). Digital pathology involves the scanning and digitization of tissue slides, allowing pathologists to review and analyze images remotely. AI algorithms can then be applied to these digital images to aid in the interpretation and analysis of tissue samples. This integration enables faster and more accurate diagnoses, enhances workflow efficiency, and improves patient care. It also facilitates the development of predictive models and precision medicine approaches. As a result, there is a growing demand for digital pathology solutions and AI-driven tissue diagnostics platforms in the market.

With technological improvements in imaging techniques, the sensitivity of detection and diagnosis of breast cancer has also improved. For instance, in May 2023, with an emphasis on AI-guided breast cancer diagnoses, BPGbio recently announced an agreement with the Department of Defense (DoD). The new panel, created with artificial intelligence, is intended to detect women diagnosed with ER+ breast cancer but do not react to hormone therapy, allowing for more suitable treatment alternatives and improving treatment response.

The unique 34-gene breast cancer diagnostic panel from BPGbio will also receive wider evaluation through the Interrogative Biology Platform, focusing on ER+ breast cancers, which are significantly rising. Technological expansion in breast tissue analysis includes procedures for evaluating gene expression, cellular biochemistry, and molecular biology using digital methods, tomosynthesis, CAD, and other methods.

Tissue Diagnostics Market Report Highlights:

• The immunohistochemistry segment dominated the market in terms of revenue share of 25.79% in 2024. Immunohistochemistry (IHC) is a special staining test in which a diagnostic antibody is bound to a specific target protein present in cell membranes or cells on slides containing tissue samples.
• The digital pathology and workflow segment is anticipated to grow at the fastest CAGR of 12.22%. Digital pathology and workflow integration have revolutionized the application of ISH by enhancing imaging, data management, and analysis.
• The breast cancer segment held the largest market share of 50.45% in 2024 and is anticipated to grow at the fastest CAGR. The increasing incidence of breast cancer due to lifestyle changes and rapidly aging global population provide lucrative growth opportunities for the segment.
• The clinical market segment dominated the market in 2024 and is anticipated to grow at the fastest CAGR of 8.83% over the forecast period, driven by advancements in medical technology, increasing disease prevalence, and a rising demand for precise & personalized medicine.
• The hospitals dominated the market with the largest revenue share of 37.82% in 2024. The usage of tissue diagnostic systems and services in hospitals & clinics has increased over the years. In several hospitals and clinics, physicians are switching to tissue diagnostic tests from conventional testing procedures.
• North America tissue diagnostics market accounted for a 44.76% share in 2024, driven by a rising demand for advanced diagnostic tools due to the increasing prevalence of cancer and other diseases.

Table of Content

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Application Segment
    • 1.1.1.2. Technology Segment
    • 1.1.1.3. Modality Segment
    • 1.1.1.4. End use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
  • 1.3.1. Objectives
  • 1.3.2. Objective - 1
  • 1.3.3. Objective - 2
  • 1.3.4. Objective - 3
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information or Data Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Technology & Application Snapshot
• 2.3. Modality & End Use Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Worldwide increase in cancer prevalence
    • 3.2.1.2. Advancements in imaging techniques and increasing affordability of diagnostics
    • 3.2.1.3. Growth of personalized therapeutics and diagnostics
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High costs associated with R&D and clinical trials
    • 3.2.2.2. Presence of non-valued based reimbursement policy
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis

Chapter 4. Technology Business Analysis

• 4.1. Tissue Diagnostics Market: Technology Movement Analysis
• 4.2. Immunohistochemistry
  • 4.2.1. Immunohistochemistry Market, 2018 - 2030 (USD Million)
  • 4.2.2. Instruments
    • 4.2.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 4.2.2.2. Slide Staining Systems
      • 4.2.2.2.1. Slide Staining Systems Market, 2018 - 2030 (USD Million)
    • 4.2.2.3. Tissue Microarrays
      • 4.2.2.3.1. Tissue Microarrays Market, 2018 - 2030 (USD Million)
    • 4.2.2.4. Tissue Processing Systems
      • 4.2.2.4.1. Tissue Processing Systems Market, 2018 - 2030 (USD Million)
    • 4.2.2.5. Slide Scanners
      • 4.2.2.5.1. Slide Scanners Market, 2018 - 2030 (USD Million)
    • 4.2.2.6. Cell Processors
      • 4.2.2.6.1. Cell Processors Market, 2018 - 2030 (USD Million)
    • 4.2.2.7. Microtomes
      • 4.2.2.7.1. Microtomes Market, 2018 - 2030 (USD Million)
    • 4.2.2.8. Embedding Systems
      • 4.2.2.8.1. Embedding Systems Market, 2018 - 2030 (USD Million)
    • 4.2.2.9. Cover Slippers
      • 4.2.2.9.1. Cover Slippers Market, 2018 - 2030 (USD Million)
    • 4.2.2.10. Other Products
      • 4.2.2.10.1. Other Products Market, 2018 - 2030 (USD Million)
  • 4.2.3. Consumables
    • 4.2.3.1. Consumables Market, 2018 - 2030 (USD Million)
    • 4.2.3.2. H&E stainer coverslipper
      • 4.2.3.2.1. H&E stainer coverslipper Market, 2018 - 2030 (USD Million)
    • 4.2.3.3. IHC stainer coverslipper
      • 4.2.3.3.1. IHC stainer coverslipper Market, 2018 - 2030 (USD Million)
    • 4.2.3.4. Antibodies
      • 4.2.3.4.1. Antibodies Market, 2018 - 2030 (USD Million)
    • 4.2.3.5. Others
      • 4.2.3.5.1. Others Market, 2018 - 2030 (USD Million)
• 4.3. In situ Hybridization
  • 4.3.1. In situ Hybridization Market, 2018 - 2030 (USD Million)
  • 4.3.2. Instruments
    • 4.3.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 4.3.2.2. Stainers
      • 4.3.2.2.1. Stainers Market, 2018 - 2030 (USD Million)
    • 4.3.2.3. Others
      • 4.3.2.3.1. Others Market, 2018 - 2030 (USD Million)
  • 4.3.3. Consumables
    • 4.3.3.1. Consumables Market, 2018 - 2030 (USD Million)
  • 4.3.4. Software
    • 4.3.4.1. Software Market, 2018 - 2030 (USD Million)
• 4.4. Primary & Special Staining
  • 4.4.1. Primary & Special Staining Market, 2018 - 2030 (USD Million)
• 4.5. Digital Pathology & Workflow
  • 4.5.1. Digital Pathology & Workflow Market, 2018 - 2030 (USD Million)
  • 4.5.2. Image Analysis Informatics
    • 4.5.2.1. Image Analysis Informatics Market, 2018 - 2030 (USD Million)
  • 4.5.3. Information Management System Storage & Communication
    • 4.5.3.1. Information Management System Storage & Communication Market, 2018 - 2030 (USD Million)
• 4.6. Anatomic Pathology
  • 4.6.1. Anatomic Pathology Market, 2018 - 2030 (USD Million)
  • 4.6.2. Instruments
    • 4.6.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 4.6.2.2. Microtomes & Cryostat Microtomes
      • 4.6.2.2.1. Microtomes & Cryostat Microtomes Market, 2018 - 2030 (USD Million)
    • 4.6.2.3. Tissue Processors
      • 4.6.2.3.1. Tissue Processors Market, 2018 - 2030 (USD Million)
    • 4.6.2.4. Automatic Strainers
      • 4.6.2.4.1. Automatic Strainers Market, 2018 - 2030 (USD Million)
    • 4.6.2.5. Other Products
      • 4.6.2.5.1. Other Products Market, 2018 - 2030 (USD Million)
  • 4.6.3. Consumables
    • 4.6.3.1. Consumables Market, 2018 - 2030 (USD Million)
    • 4.6.3.2. Antibodies & Reagents
      • 4.6.3.2.1. Antibodies & Reagents Market, 2018 - 2030 (USD Million)
    • 4.6.3.3. Probes & Kits
      • 4.6.3.3.1. Probes & Kits Market, 2018 - 2030 (USD Million)
    • 4.6.3.4. Others
      • 4.6.3.4.1. Others Market, 2018 - 2030 (USD Million)
• 4.7. Molecular Pathology
  • 4.7.1. Anatomic Pathology Market, 2018 - 2030 (USD Million)
  • 4.7.2. Instruments
    • 4.7.2.1. Instruments Market, 2018 - 2030 (USD Million)
  • 4.7.3. Reagents
    • 4.7.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 4.7.3.2. Fluorescence Reagents
      • 4.7.3.2.1. Fluorescence Reagents Market, 2018 - 2030 (USD Million)
    • 4.7.3.3. Others
      • 4.7.3.3.1. Others Market, 2018 - 2030 (USD Million)
  • 4.7.4. Others
    • 4.7.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

• 5.1. Tissue Diagnostics Market: Application Movement Analysis
• 5.2. Breast Cancer
  • 5.2.1. Breast Cancer Market, 2018 - 2030 (USD Million)
• 5.3. Non-Small Cell Lung Cancer
  • 5.3.1. Non-Small Cell Lung Cancer Market, 2018 - 2030 (USD Million)
• 5.4. Prostate Cancer
  • 5.4.1. Prostate Cancer Market, 2018 - 2030 (USD Million)
• 5.5. Gastric Cancer
  • 5.5.1. Gastric Cancer Market, 2018 - 2030 (USD Million)
• 5.6. Other Cancers
  • 5.6.1. Other Cancers Technology Market, 2018 - 2030 (USD Million)

Chapter 6. Modality Business Analysis

• 6.1. Tissue Diagnostics Market: Modality Movement Analysis
• 6.2. Clinical
  • 6.2.1. Clinical Market, 2018 - 2030 (USD Million)
• 6.3. Pharma / CRO / Research market
  • 6.3.1. Pharma / CRO / Research Market, 2018 - 2030 (USD Million)

Chapter 7. End Use Business Analysis

• 7.1. Hospitals
  • 7.1.1. Hospitals Market, 2018 - 2030 (USD Million)
• 7.2. Diagnostic Center
  • 7.2.1. Diagnostic Center Market, 2018 - 2030 (USD Million)
• 7.3. Pharmaceutical Organizations
  • 7.3.1. Pharmaceutical Organizations Market, 2018 - 2030 (USD Million)
• 7.4. CRO
  • 7.4.1. CRO Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Tissue Diagnostics Market Share By Region, 2024 & 2030
• 8.2. North America
  • 8.2.1. SWOT Analysis
  • 8.2.2. North America Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.2.3. U.S.
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Target Disease Prevalence
    • 8.2.3.3. Competitive Scenario
    • 8.2.3.4. Regulatory Framework
    • 8.2.3.5. U.S. Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Target Disease Prevalence
    • 8.2.4.3. Competitive Scenario
    • 8.2.4.4. Regulatory Framework
    • 8.2.4.5. Mexico Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.2.5. Canada
    • 8.2.5.1. Key Country Dynamics
    • 8.2.5.2. Target Disease Prevalence
    • 8.2.5.3. Competitive Scenario
    • 8.2.5.4. Regulatory Framework
    • 8.2.5.5. Canada Tissue Diagnostics Market, 2018 - 2030 (USD Million)
• 8.3. Europe
  • 8.3.1. SWOT Analysis
  • 8.3.2. Europe Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.3.3. UK
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Target Disease Prevalence
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. UK Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.3.4. Germany
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Target Disease Prevalence
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. Germany Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.3.5. Spain
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Target Disease Prevalence
    • 8.3.5.3. Competitive Scenario
    • 8.3.5.4. Regulatory Framework
    • 8.3.5.5. Spain Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.3.6. France
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Target Disease Prevalence
    • 8.3.6.3. Competitive Scenario
    • 8.3.6.4. Regulatory Framework
    • 8.3.6.5. France Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.3.7. Italy
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Target Disease Prevalence
    • 8.3.7.3. Competitive Scenario
    • 8.3.7.4. Regulatory Framework
    • 8.3.7.5. Italy Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.3.8. Denmark
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Target Disease Prevalence
    • 8.3.8.3. Competitive Scenario
    • 8.3.8.4. Regulatory Framework
    • 8.3.8.5. Denmark Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.3.9. Sweden
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Target Disease Prevalence
    • 8.3.9.3. Competitive Scenario
    • 8.3.9.4. Regulatory Framework
    • 8.3.9.5. Sweden Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.3.10. Norway
    • 8.3.10.1. Key Country Dynamics
    • 8.3.10.2. Target Disease Prevalence
    • 8.3.10.3. Competitive Scenario
    • 8.3.10.4. Regulatory Framework
    • 8.3.10.5. Norway Tissue Diagnostics Market, 2018 - 2030 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. SWOT Analysis
  • 8.4.2. Asia Pacific Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.4.3. Japan
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. Japan Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.4.4. China
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. China Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.4.5. India
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Target Disease Prevalence
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. India Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.4.6. South Korea
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Target Disease Prevalence
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. South Korea Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.4.7. Australia
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Target Disease Prevalence
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. Australia Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.4.8. Thailand
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Target Disease Prevalence
    • 8.4.8.3. Competitive Scenario
    • 8.4.8.4. Regulatory Framework
    • 8.4.8.5. Thailand Tissue Diagnostics Market, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1. SWOT Analysis
  • 8.5.2. Latin America Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.5.3. Brazil
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. Brazil Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.5.4. Argentina
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Regulatory Framework
    • 8.5.4.5. Argentina Tissue Diagnostics Market, 2018 - 2030 (USD Million)
• 8.6. MEA
  • 8.6.1. SWOT Analysis
  • 8.6.2. MEA Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.6.3. South Africa
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. South Africa Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Competitive Scenario
    • 8.6.4.4. Regulatory Framework
    • 8.6.4.5. UAE Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.6.5. Saudi Arabia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Competitive Scenario
    • 8.6.5.4. Regulatory Framework
    • 8.6.5.5. Saudi Arabia Tissue Diagnostics Market, 2018 - 2030 (USD Million)
  • 8.6.6. Kuwait
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Competitive Scenario
    • 8.6.6.4. Regulatory Framework
    • 8.6.6.5. Kuwait Tissue Diagnostics Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Share Analysis, 2022
• 9.4. Company Profiles/Listing
  • 9.4.1. F. Hoffmann-La Roche Ltd.
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.1.3. Technology Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Abbott Laboratories
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.2.3. Technology Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Thermo Fisher Scientific, Inc.
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.3.3. Technology Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Siemens
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.4.3. Technology Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Danaher Corporation
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.5.3. Technology Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. bioMerieux SA
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.6.3. Technology Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. QIAGEN
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.7.3. Technology Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. BD
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.8.3. Technology Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Merck KGaA
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.9.3. Technology Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. GE Healthcare
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.10.3. Technology Benchmarking
    • 9.4.10.4. Strategic Initiatives
  • 9.4.11. BioGenex
    • 9.4.11.1. Overview
    • 9.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.11.3. Technology Benchmarking
    • 9.4.11.4. Strategic Initiatives
  • 9.4.12. Cell Signaling Technology, Inc.
    • 9.4.12.1. Overview
    • 9.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.12.3. Technology Benchmarking
    • 9.4.12.4. Strategic Initiatives
  • 9.4.13. Bio SB
    • 9.4.13.1. Overview
    • 9.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.13.3. Technology Benchmarking
    • 9.4.13.4. Strategic Initiatives
  • 9.4.14. DiaGenic ASA
    • 9.4.14.1. Overview
    • 9.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.14.3. Technology Benchmarking
    • 9.4.14.4. Strategic Initiatives
  • 9.4.15. Agilent Technologies, Inc
    • 9.4.15.1. Overview
    • 9.4.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.15.3. Technology Benchmarking
    • 9.4.15.4. Strategic Initiatives